Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non-small-cell lung cancer

Molecular Pharmacology

Volumn 72, Issue 3, 2007, Pages 769-779

  Siegfried, Jill M ^a,b   Gubish, Christopher T ^a   Rothstein, Mary E ^a   De Oliveira, Pierre E Queiroz ^a   Stabile, Laura P ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT BINDING FACTOR; CYCLIC AMP; CYCLOOXYGENASE 2; DACTINOMYCIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROSTAGLANDIN E2; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR AP 1;

ARTICLE; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CYCLOOXYGENASE 2; ENZYME ACTIVATION; ENZYME INDUCTION; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 34548304315     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.034215     Document Type: Article

References (61)

1. Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, and Laterra J (2002) In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 16:108-110.
2. Abounader R, Ranganathan S, Lal B, Fielding K, Book A, Dietz H, Burger P, and Laterra J (1999) Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst 91:1548-1556.
3. Atabey N, Gao Y, Yao ZJ, Breckenridge D, Soon L, Soriano JV, Burke TR Jr, and Bottaro DP (2001) Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J Biol Chem 276:14308- 14314.
4. Bardelli A, Longati P, Gramaglia D, Basilico C, Tamagnone L, Giordano S, Ballinari D, Michieli P, and Comoglio PM (1998) Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proc Natl Acad Sci U S A 95:14379-14383.
5. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, and Aaronson SA (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:802-804.
6. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, et al. (2006) Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 66:1721-1729.
7. Chen JH, Chew-Wun W, Kao HL, Chang HM, Li AFY, Liu TY, and Chi CW (2006) Effects of COX-2 inhibitor on growth of human gastric cancer cells and its relation to hepatocyte growth factor. Cancer Lett 239:263-270.
8. Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159.
9. Christensen JG, Burrows J, and Salgia R (2005) c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225: 1-26.
10. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, et al. (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63:7345-7355.
11. Date K, Matsumoto K, Shimura H, Tanaka M, and Nakamura T (1997) HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 420:1-6.
12. Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L, Nordlinger B, Bretti S, Bottardi S, Giordano S, et al. (1995) Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1:147-154.
13. Dixon DA (2004) Dysregulated post-transcriptional control of COX-2 gene expression in cancer. Curr Pharm Des 10:635-646.
14. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, and Lipsky PE (1998) Cyclooxygenase in biology and disease. FASEB J 12:1063-1073.
15. Furge KA, Zhang YW, and Vande Woude GF (2000) Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 19:5582-5589.
16. Furukawa T, Duguid WP, Kobari M, Matsuno S, and Tsao MS (1995) Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am J Pathol 147:889-895.
17. Gardner KH and Montminy M (2005) Can you hear me now? Regulating transcriptional activators by phosphorylation. Sci STKE 301:pe44.
18. Han C, Michalopoulos GK, and Wu T (2006) Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol 207:261-270.
19. Hiscox S, Parr C, Nakamura T, Matsumoto K, Mansel RE, and Jiang WG (2000) Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4. Breast Cancer Res Treat 59:245-254.
20. Ichimura E, Maeshima A, Nakajima T, and Nakamura T (1996) Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 87:1063-1069.
21. Jiang WG, Hiscox SE, Parr C, Martin TA, Matsumoto K, Nakamura T, and Mansel RE (1999) Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clin Cancer Res 5:3695-3703.
22. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, and Strom SC (2000) Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 275:8806-8811.
23. Johannessen M and Moens U (2007) Multisite phosphorylation of the cAMP response element-binding protein (CREB) by a diversity of protein kinases. Front Biosci 12:1814-1832.
24. Jones MK, Sasaki E, Halter F, Pai R, Nakamura T, Arakawa T, Kuroki T, and Tarnawski AS (1999) HGF triggers activation of the COX-2 gene in rat gastric epithelial cells: action mediated through the ERK2 signaling pathway. FASEB J 13:2186-2194.
25. Kamiyama M, Pozzi A, Yang L, DeBusk LM, Breyer RM, and Lin PC (2006) EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene 25:7019-7028.
26. Kaplan O, Firon M, Vivi A, Navon G, and Tsarfaty I (2000) HGF/SF activates glycolysis and oxidative phosphorylation in DA3 murine mammary cancer cells. Neoplasia 2:365-377.
27. Khan MF, Kannan S, and Wang J (2006) Activation of transcription factor AP-1 and mitogen-activated protein kinases in aniline-induced splenic toxicity. Toxicol Appl Pharmacol 210:86-93.
28. Kim KJ, Wang L, Su YC, Gillespie GY, Salhotra A, Lal B, and Laterra J (2006) Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 12:1292-1298.
29. Konturek PC, Kania J, Kukharsky V, Ocker S, Hahn EG, and Konturek SJ (2003) Influence of gastrin on the expression of cyclooxygenase-2, hepatocyte growth factor and apoptosis-related proteins in gastric epithelial cells. J Physiol Pharmacol 54:17-32.
30. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, and Dubinett SM (2005) Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small-cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 65:6275-6281.
31. Krysan K, Reckamp KL, Sharma S, and Dubinett SM (2006) The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem 6:209-220.
32. Ma PC (2004) c-MET expression/activation, functions, and mutations in non-small-cell lung cancer. Proc Am Assoc Cancer Res 44:1875.
33. Ma PC (2005) Selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res 11:3212-3219.
34. Martey CA, Pollock SJ, Turner CK, O'Reilly KM, Baglole CJ, Phipps RP, and Sime PJ (2004) Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. Am J Physiol Lung Cell Mol Physiol 287:L981-L991.
35. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, and Comoglio PM (2004) Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6:61-73.
36. Mifflin RC, Saada JI, Di Mari JF, Adegboyega PA, Valentich JD, and Powell DW (2002) Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-mediated induction. Am J Physiol Cell Physiol 282:C824-C834.
37. Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, and Powell DW (2004) Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol 65:470-478.
38. Nakanishi K, Fujimoto J, Ueki T, Kishimoto K, Hashimoto-Tamaoki T, Furuyama J, Itoh T, Sasaki Y, and Okamoto E (1999) Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase. Clin Exp Metastasis 17:507-514.
39. Pai R, Nakamura T, Moon WS, and Tarnawski AS (2003) Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J 17:1640-1647.
40. Parr C, Hiscox S, Nakamura T, Matsumoto K, and Jiang WG (2000) Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. Int J Cancer 85:563-570.
41. Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, Gherardi E, and Birchmeier C (1995) Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373:699-702.
42. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, et al. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73.
43. Segarra J, Balenci L, Drenth T, Maina F, and Lamballe F (2006) Combined signaling through ERK, PI3K/AKT, and RAC1/p38 is required for met-triggered cortical neuron migration. J Biol Chem 281:4771-4778.
44. Shiff SJ, Shivaprasad P, and Santini DL (2003) Cyclooxygenase inhibitors: drugs for cancer prevention. Curr Opin Pharmacol 3:352-361.
45. Siegfried JM, Krishnamachary N, Gaither-Davis A, Gubish C, Hunt JD, and Shriver SP (1999) Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small-cell lung cancer. Pulm Pharmacol Ther 12:291-302.
46. Siegfried JM, Luketich JD, Stabile LP, Christie N, and Land SR (2004) Elevated hepatocyte growth factor level correlates with poor outcome in early-stage and late-stage adenocarcinoma of the lung. Chest 125 (5 Suppl):116S-119S.
47. Siegfried JM, Weissfeld LA, Singh-Kaw P, Weyant RJ, Testa JR, and Landreneau RJ (1997) Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small-cell lung cancer. Cancer Res 57:433-439.
48. Singh-Kaw P, Zarnegar R, and Siegfried JM (1995) Stimulatory effects of hepatocyte growth factor on normal and neoplastic human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 268 (6 Pt 1):L1012-L1020.
49. Sonnenberg E, Meyer D, Weidner KM, and Birchmeier C (1993) Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 123:223-235.
50. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, and Siegfried JM (2005) Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small-cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65:1459-1470.
51. Stabile LP, Lyker JS, Huang L, and Siegfried JM (2004) Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy. Gene Ther 11:325-335.
52. Stabile LP, Lyker JS, Land SR, Dacic S, Zamboni BA, and Siegfried JM (2006) Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. Carcinogenesis 27:1547-1555.
53. Subbaramaiah K and Dannenberg AJ (2003) Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24:96-102.
54. Subbaramaiah K, Marmo TP, Dixon DA, and Dannenberg AJ (2003) Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem 278:37637-37647.
55. Tazawa R, Xu XM, Wu KK, and Wang LH (1994) Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun 203:190-199.
56. Thomas SM, Bhola NE, Zhang Q, Contrucci SC, Wentzel AL, Freilino ML, Gooding WE, Siegfried JM, Chan DC, and Grandis JR (2006) Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res 66:11831-11839.
57. Thomas SM, Grandis JR, Wentzel AL, Gooding WE, Lui VW, and Siegfried JM (2005) Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia 7:426-431.
58. Twombly R (2005) Failing survival advantage in crucial trial, future of Iressa is in jeopardy. J Natl Cancer Inst 97:249-250.
59. Webb CP, Van Aelst L, Wigler MH, and Woude GF (1998) Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc Natl Acad Sci U S A 95:8773-8778.
60. Yoshimoto A, Kasahara K, Kawashima A, Fujimura M, and Nakao S (2005) Characterization of the prostaglandin biosynthetic pathway in non-small-cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases. Oncol Rep 13:1049-1057.
61. Zhang Q, Thomas SM, Lui VWY, Xi S, Siegfried JM, Fan H, Smithgall TE, Mills GB, and Grandis JR (2006) Phosphorylation of TNF-α converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci U S A 103:6901-6906.